Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 56 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 34
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 25
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 21
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access | Times Cited: 2
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen
Endocrinology and Metabolism (2024) Vol. 39, Iss. 1, pp. 12-22
Open Access | Times Cited: 14
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
Eric Lawitz, Mandy Fraessdorf, Guy Neff, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. 837-846
Open Access | Times Cited: 14
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2001-2016
Closed Access | Times Cited: 11
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Prathima Gogineni, Eka Melson, Dimitris Papamargaritis, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 7, pp. 801-818
Open Access | Times Cited: 8
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
Emmanouil Koullias, Maria Papavdi, John Koskinas, et al.
Cureus (2025)
Open Access | Times Cited: 1
New Lessons from the gut: Studies of the role of gut peptides in weight loss and diabetes resolution after gastric bypass and sleeve gastrectomy
Jens J. Holst, Sten Madsbad, Kirstine N. Bojsen‐Møller, et al.
Peptides (2024) Vol. 176, pp. 171199-171199
Open Access | Times Cited: 6
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease
Kitt Falk Petersen, Sylvie Dufour, Wajahat Z. Mehal, et al.
Cell Metabolism (2024) Vol. 36, Iss. 11, pp. 2359-2366.e3
Closed Access | Times Cited: 6
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son, Soo Lim
Endocrinology and Metabolism (2024) Vol. 39, Iss. 2, pp. 206-221
Open Access | Times Cited: 5
An Exhaustive Exploration of the Semaglutide-GLP-1R Sequence Space towards the Design of Semaglutide Analogues with Elevated Binding Affinity to GLP-1R
Wei Li
(2024)
Open Access | Times Cited: 4
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future
James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, et al.
Medicinal Research Reviews (2024) Vol. 45, Iss. 1, pp. 29-65
Open Access | Times Cited: 4
Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis
Zhige Wen, Wenjie Sun, Haoshuo Wang, et al.
Diabetes Research and Clinical Practice (2025), pp. 111999-111999
Closed Access
Análise das diferentes respostas ao tratamento com agonistas GLP-1 em diabetes tipo 1 e tipo 2 e a personalização dos tratamentos
G. F. de Carvalho, GUSTAVO PACIFICO MAIA ANTERO DE SOUSA, Gabriel Moraes, et al.
Contribuciones a las Ciencias Sociales (2025) Vol. 18, Iss. 1, pp. e14682-e14682
Closed Access
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Juan José Gorgojo Martínez
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 678-678
Open Access
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation
Maedeh Movahednasab, Hassan Dianat‐Moghadam, Sana Khodadad, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top